Dirk J. de Jong

Radboud University Nijmegen — Netherlands

Biochemistry, Genetics and Molecular Biology · Life Sciences

49h-index7.9kcitations214works3.52yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Inflammatory Bowel Disease(134), Microscopic Colitis(77), Acute Lymphoblastic Leukemia research(29), Eosinophilic Esophagitis(24), Immunodeficiency and Autoimmune Disorders(20)

Publications214 total

Su1849: LONG-TERM OUTCOMES OF EXTENDED VERSUS CONVENTIONAL ADALIMUMAB DOSE INTERVAL FOR PATIENTS WITH CROHN’S DISEASE IN STABLE REMISSION: 3-YEAR FOLLOW-UP OF THE RANDOMIZED CONTROLLED LADI TRIAL
Gastroenterology·2025
Surveillance in inflammatory bowel disease: white light endoscopy with segmental re-inspection versus dye-based chromoendoscopy – a multi-arm randomised controlled trial (HELIOS)
Gut·2025· 9 citedOpen Access
A Prediction Model for Successful Increase of Adalimumab Dose Intervals in Patients with Crohn’s Disease: Secondary Analysis of the Pragmatic Open-Label Randomised Controlled Non-inferiority LADI Trial
Digestive Diseases and Sciences·2024· 2 citedOpen Access
Multisegmented esophageal fully covered self-expandable metal stent for palliation of malignant dysphagia: a prospective, multicenter feasibility and safety study
Gastrointestinal Endoscopy·2024· 3 citedOpen Access
Cost-Effectiveness Analysis of Increased Adalimumab Dose Intervals in Crohn’s Disease Patients in Stable Remission: The Randomized Controlled LADI Trial
Journal of Crohn s and Colitis·2023· 4 citedOpen Access
Feasibility of Reduced Clinical Monitoring in Patients with Inflammatory Bowel Disease Treated with Thiopurine Therapy
Digestive Diseases and Sciences·2023· 1 citedOpen Access
Increased versus conventional adalimumab dose interval for patients with Crohn's disease in stable remission (LADI): a pragmatic, open-label, non-inferiority, randomised controlled trial
˜The œLancet. Gastroenterology & hepatology·2023· 19 citedOpen Access
Tu1498: WITHDRAWAL OF THIOPURINES IN INFLAMMATORY BOWEL DISEASE PATIENTS IN STABLE REMISSION: A PROSPECTIVE, MULTICENTER COHORT STUDY
Gastroenterology·2022
P512 Safety of reduced clinical monitoring in patients with stable Inflammatory Bowel Disease on maintenance thiopurine therapy
Journal of Crohn s and Colitis·2021Open Access
Clinical Outcomes of Covid-19 in Patients With Inflammatory Bowel Disease: A Nationwide Cohort Study
Journal of Crohn s and Colitis·2020· 70 citedOpen Access
High-Dose Vitamin D Does Not Prevent Postoperative Recurrence of Crohn’s Disease in a Randomized Placebo-Controlled Trial
Clinical Gastroenterology and Hepatology·2020· 34 citedOpen Access
Lengthening adalimumab dosing interval in quiescent Crohn’s disease patients: protocol for the pragmatic randomised non-inferiority LADI study
BMJ Open·2020· 6 citedOpen Access
1028 USTEKINUMAB IS ASSOCIATED WITH BETTER EFFECTIVENESS OUTCOMES WHEN COMPARED TO VEDOLIZUMAB IN CROHN'S DISEASE PATIENTS WITH PRIOR FAILURE TO ANTI-TNF: A COMPARATIVE EFFECTIVENESS STUDY FROM THE DUTCH ICC REGISTRY
Gastroenterology·2020
Limited added value of laboratory monitoring in thiopurine maintenance monotherapy in inflammatory bowel disease patients
Alimentary Pharmacology & Therapeutics·2020· 8 citedOpen Access
Vedolizumab for Inflammatory Bowel Disease: Two‐Year Results of the Initiative on Crohn and Colitis (ICC) Registry, A Nationwide Prospective Observational Cohort Study
Clinical Pharmacology & Therapeutics·2019· 33 citedOpen Access
Real‐life study of safety of thiopurine‐allopurinol combination therapy in inflammatory bowel disease: myelotoxicity and hepatotoxicity rarely affect maintenance treatment
Alimentary Pharmacology & Therapeutics·2019· 22 citedOpen Access
Genetic deficiency of NOD2 confers resistance to invasive aspergillosis
Nature Communications·2018· 56 citedOpen Access
Drug Survival and Immunogenicity After Switching From Remicade to Biosimilar CT-P13 in Inflammatory Bowel Disease Patients: Two-year Follow-up of a Prospective Observational Cohort Study
Inflammatory Bowel Diseases·2018· 32 cited
Mo1844 - Drug Survival and Immunogenicity after Switching from Remicade ® to Biosimilar Ct-P13 in Inflammatory Bowel Disease Patients: Two Year Follow-Up of a Prospective Observational Cohort Study
Gastroenterology·2018
Sa1691 - Monitoring of Laboratory Parameters During Thiopurine Maintenance Therapy in Patietns with Inflammatory Bowel Disease: An Unnecessary Burden?
Gastroenterology·2018
page 1 of 11Next →

Frequent Co-authors

C. Janneke van der Woude(16), Bas Oldenburg(16), Gerard Dijkstra(14), Pieter Stokkers(12), Ad A. van Bodegraven(12), Mihai G. Netea(10), Peter D. Siersema(9), Joost P.H. Drenth(9), Marieke Pierik(8), Jeroen M. Jansen(8), Nofel Mahmmod(8), Andrea E. van der Meulen‐de Jong(8), Cyriel Y. Ponsioen(8), Herma H. Fidder(7), Mariëlle Romberg‐Camps(7), Paul C. van de Meeberg(7), Gerben Ferwerda(7), Bart Jan Kullberg(7), Daan W. Hommes(6), Rinse K. Weersma(6)